Arrowhead Pharmaceuticals, Inc.
ARWR
株式のランク
#2369
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
株価
$59.06
時価総額
$8.34B
変化（1日）
3.20%
変化（1年）
53.52%
国
US
取引 Arrowhead Pharmaceuticals, Inc. (ARWR)
カテゴリー
Healthcare
Arrowhead Pharmaceuticals, Inc.（ARWR）のP/B比率
October 2026 時点のP/B比率 TTM: 17.98
Arrowhead Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 17.98 です。2024 年末時点でのP/B比率は 12.51 でした。
Arrowhead Pharmaceuticals, Inc. の P/B 比率の履歴（2000 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 17.98 | 81.59% |
| 2025 | 9.90 | -20.88% |
| 2024 | 12.51 | 17.74% |
| 2023 | 10.63 | 21.54% |
| 2022 | 8.74 | -44.81% |
| 2021 | 15.84 | 68.68% |
| 2020 | 9.39 | -13.15% |
| 2019 | 10.81 | -35.53% |
| 2018 | 16.77 | 331.15% |
| 2017 | 3.89 | -17.05% |
| 2016 | 4.69 | 56.40% |
| 2015 | 3.00 | -27.91% |
| 2014 | 4.16 | -16.08% |
| 2013 | 4.96 | 73.69% |
| 2012 | 2.85 | 30.51% |
| 2011 | 2.19 | -70.72% |
| 2010 | 7.47 | 20.79% |
| 2009 | 6.18 | 86.63% |
| 2008 | 3.31 | -51.41% |
| 2007 | 6.82 | 31.15% |
| 2006 | 5.20 | 78.93% |
| 2005 | 2.91 | -62.49% |
| 2004 | 7.75 | 23,160.06% |
| 2003 | 0.03 | -309.43% |
| 2002 | -0.02 | -82.15% |
| 2001 | -0.09 | -82.46% |
| 2000 | -0.51 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -65.23% |
US
|
|
| 13.2547 | -26.27% |
US
|
|
| 4.208 | -76.59% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -65.61% |
NL
|
